Navigation Links
IDM Pharma Reports Third Quarter 2007 Financial Results
Date:11/8/2007

IRVINE, Calif., Nov. 8 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced its financial results for the quarter and nine months ended September 30, 2007. Financial information presented represents the consolidated results of IDM Pharma and its subsidiary, IDM S.A.

Cash and cash equivalents totaled $33.2 million as of September 30, 2007 compared to $37.3 million on June 30, 2007 and $10.2 million on December 31, 2006. The Company's net cash outflow from operations and investment activities for the quarter and nine months ended September 30, 2007, which excludes cash received from financing activities and the effect of exchange rates, was approximately $5.1 million and $14.3 million, respectively.

"During the third quarter we announced our intention to collect additional survival data from the L-MTP-PE Phase 3 trial and submit an amendment to the NDA in the first quarter of 2008," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "In addition, we announced the appointment of Jeff Sherman as our chief medical officer who brings valuable expertise to the management team as we work through the regulatory approval process for L-MTP-PE in the U.S. and Europe, and as we develop our oncology pipeline."

Quarter Ended September 30, 2007

Total revenues in the third quarter of 2007 were $3.1 million compared to total revenues of $3.0 million for the quarter ended September 30, 2006. Substantially all of the revenues for both periods were derived from the Company's collaboration agreement with sanofi-aventis. The $0.1 million increase in revenues in the 2007 period was due to an increase in development costs related to UVIDEM clinical trials, which are reimbur
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The microscopy market is estimated to grow at ... by 2019. Optical microscopy is the largest segment ... segment is expected to show the fastest growth ... nanotechnology, technological advancements, and increasing federal support to ... Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... of the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ... Liebhard LLP reports. According to an Order issued in ... November 20th, the Court will convene an open conference ... Federal Building and United States Courthouse in West Palm ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas Sale, ... has chosen their best-selling lace wedding dresses, vintage bridesmaid ... season. , Now, BellasDress.com features popular women’s dresses, ... discount prices. The business hopes everyone can have a ... , “All our elegant products are made with exquisite ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... chronic illnesses can receive effective, less expensive care from a ... to a team of dedicated health care professionals, a new ... ill and need either hospitalization or a trip to the ... home clinic at the University of Texas in Houston versus ...
(Date:12/25/2014)... December 25, 2014 AngelWeddingDress.com tries its ... the online realm. Today, the business has introduced its ... site-wide prom dress promotion. , The new prom outfits ... and every dress lover. They are specially designed for ... prom dresses should visit its website before Jan. ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... , DETROIT, Sept. 21 Webahn, Inc. announces ... for its online Electronic Medical Records service Capzule.com and Accent, ... , , Capzule enables physicians to ... also has the capability to send messages, add notes, prescribe ...
... (DVT) is a serious condition that involves the formation of ... the legs. A patient with DVT is typically treated with ... radiology procedures may play a more central role in the ... the October issue of the American Journal of Roentgenology ...
... Bradley Cooper, Soleil Moon Frye, Terrell Owens, ... Pierce Strut Purple for Alzheimer,s Association , , ... new data released estimates 35 million people worldwide -- a 10% ... the urgent need for action and response. , , ...
... NEW ORLEANS, Sept. 20 Jack Mackenroth, from the ... the 20th annual NO/AIDS Walk and is bringing Living Positive ... the city. On Sunday, September 20th, Jack will participate in the ... as several other AIDS Service Organizations in Louisiana each year. The ...
... with advanced non-small-cell tumors, study finds, , SATURDAY, Sept. ... pemetrexed improves the survival of people with non-small-cell lung ... new study has found.</p, Nearly 90 percent of all ... At the time the cancer is discovered, it,s considered ...
... Lift ... collection of lift chairs and other mobility products. , ... Raleigh, NC (PRWEB) September 19, 2009 -- Lift Chairs 101, a leader in sales ... , offering a variety of styles and prices in order to better meet the mobility needs ...
Cached Medicine News:Health News:Voice, Medical Records iPhone Apps Launched for Physicians 2Health News:Image-guided treatment for deep venous thrombosis could improve patients' long-term outcomes 2Health News:Celebrities Vie For 'Who Wears Purple Best?' Title to Raise Awareness of New Global Prevalence On World Alzheimer's Day 2Health News:Celebrities Vie For 'Who Wears Purple Best?' Title to Raise Awareness of New Global Prevalence On World Alzheimer's Day 3Health News:REPEAT: 'Project Runway' Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positive By Design 2Health News:REPEAT: 'Project Runway' Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positive By Design 3Health News:New Drug May Offer Hope to Some With Lung Cancer 2Health News:Lift Chairs 101 Introduces New Bathtub Lift Line 2
(Date:12/24/2014)... Dec. 23, 2014  Medical Science Liaisons play a ... link between the medical device industry and key stakeholders, ... the coming years as the device industry relies on ... to research by benchmarking firm, Best Practices, LLC, one ... important edge is by harnessing new technology to enable ...
(Date:12/22/2014)... LAWRENCE, Mass. , Dec. 22, 2014 /PRNewswire/ ... a leading manufacturer of innovative dialysis products, announced ... (FDA) has cleared its System One™ to perform ... sleeping, known as home nocturnal hemodialysis. NxStage,s® System ... cleared by the FDA for this indication. ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "US Self-monitoring Blood Glucose Market" report to their ... This market insight focuses on the developments in ... United States . Reimbursement analysis and the effects ... for more than 73 SMBG meters have been performed, ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3US Self-monitoring Blood Glucose Market 2
... COLLEGEVILLE, Pa., and TARRYTOWN, N.Y., May 22 ... ), and Progenics,Pharmaceuticals, Inc. (Nasdaq: PGNX ), ... with investigational oral and,intravenous formulations of RELISTOR(TM) (methylnaltrexone ... phase 2 trial, evaluated the effects of,an oral ...
... LAS VEGAS, May 22 CardioVascular,BioTherapeutics, Inc. (OTC Bulletin ... Christopher Moore to be the sponsor and general,partner of ... of,$1 million and up to $10 million of the ... am extremely impressed with CVBT,s wound healing drug, which ...
Cached Medicine Technology:Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 2Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 3Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 4Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 5Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 6Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 7Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 2Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 3
Cloward cervical retractor. Size 18 mm....
Large, removable blades, length 242 mm, (9 1/2"). Function: tissue retracting....
Toothed Pituitary IVD Rongeurs, 8 length 200 mm....
Suitable for children and adults. New mechanical design of the skull pin holder and the clamp base ensures improved rigid skull fixation....
Medicine Products: